Key result
Deployment of the Supralimus-Core sirolimus-eluting stent in an unselected real-world population demonstrated a 12-month major adverse cardiac event rate of 3.4%.
Why the study?
Does the Supralimus-Core sirolimus-eluting stent provide safe and effective outcomes in patients undergoing percutaneous coronary intervention?
Population
562 patients undergoing single or multi-vessel percutaneous coronary intervention for coronary artery…
Design
Cohort
Follow-up
12 months
Authors
Loading...
Supports real-world use consideration; leaves open need for randomized confirmation of safety and efficacy.
Observational (n=562)
Yes
Does the Supralimus-Core sirolimus-eluting stent provide safe and effective outcomes in patients undergoing percutaneous coronary intervention?
The cobalt-chromium biodegradable polymer-based sirolimus-eluting stent demonstrated low rates of major adverse cardiac events (3.4%) and stent thrombosis (0.4%) at 12 months in a real-world PCI population.
Chandwani et al. (2014) conducted an observational in coronary artery disease (n=562). Supralimus-Core sirolimus-eluting stent was evaluated on major adverse cardiac events (MACE), defined as the composite of cardiac death, myocardial infarction (MI), target lesion revascularisation (TLR) and target vessel revascularisation (TVR) at 12-month post-procedure. Deployment of the Supralimus-Core sirolimus-eluting stent in an unselected real-world population demonstrated a 12-month major adverse cardiac event rate of 3.4%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: